128 related articles for article (PubMed ID: 31366440)
1. Impact of mutations in hVISA isolates on decreased susceptibility to vancomycin, through population analyses profile - area under curve (PAP-AUC).
Silveira ACO; Caierão J; Silva CI; Anzai EK; McCulloch JA; d'Azevedo PA; Sincero TCM
Diagn Microbiol Infect Dis; 2019 Nov; 95(3):114854. PubMed ID: 31366440
[TBL] [Abstract][Full Text] [Related]
2. Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3.
Matsuo M; Hishinuma T; Katayama Y; Cui L; Kapi M; Hiramatsu K
Antimicrob Agents Chemother; 2011 Sep; 55(9):4188-95. PubMed ID: 21746940
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of amino acid changes in the yvqF, vraSR, graSR, and tcaRAB genes from vancomycin intermediate resistant Staphylococcus aureus.
Yoo JI; Kim JW; Kang GS; Kim HS; Yoo JS; Lee YS
J Microbiol; 2013 Apr; 51(2):160-5. PubMed ID: 23625215
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3.
Matsuo M; Cui L; Kim J; Hiramatsu K
Antimicrob Agents Chemother; 2013 Dec; 57(12):5843-53. PubMed ID: 24018261
[TBL] [Abstract][Full Text] [Related]
5. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus.
Hafer C; Lin Y; Kornblum J; Lowy FD; Uhlemann AC
Antimicrob Agents Chemother; 2012 Nov; 56(11):5845-51. PubMed ID: 22948864
[TBL] [Abstract][Full Text] [Related]
6. Impact of vancomycin use trend change due to the availability of alternative antibiotics on the prevalence of Staphylococcus aureus with reduced vancomycin susceptibility: a 14-year retrospective study.
Kang YR; Kim SH; Chung DR; Ko JH; Huh K; Cho SY; Kang CI; Peck KR
Antimicrob Resist Infect Control; 2022 Aug; 11(1):101. PubMed ID: 35932086
[TBL] [Abstract][Full Text] [Related]
7. Role of stop codons in development and loss of vancomycin non-susceptibility in methicillin-resistant Staphylococcus aureus.
Doddangoudar VC; O'Donoghue MM; Chong EY; Tsang DN; Boost MV
J Antimicrob Chemother; 2012 Sep; 67(9):2101-6. PubMed ID: 22643192
[TBL] [Abstract][Full Text] [Related]
8. Complete Reconstitution of the Vancomycin-Intermediate Staphylococcus aureus Phenotype of Strain Mu50 in Vancomycin-Susceptible S. aureus.
Katayama Y; Sekine M; Hishinuma T; Aiba Y; Hiramatsu K
Antimicrob Agents Chemother; 2016 Jun; 60(6):3730-42. PubMed ID: 27067329
[TBL] [Abstract][Full Text] [Related]
9. Dissecting vancomycin-intermediate resistance in staphylococcus aureus using genome-wide association.
Alam MT; Petit RA; Crispell EK; Thornton TA; Conneely KN; Jiang Y; Satola SW; Read TD
Genome Biol Evol; 2014 Apr; 6(5):1174-85. PubMed ID: 24787619
[TBL] [Abstract][Full Text] [Related]
10. Genomic insights on heterogeneous resistance to vancomycin and teicoplanin in Methicillin-resistant Staphylococcus aureus: A first report from South India.
Bakthavatchalam YD; Babu P; Munusamy E; Dwarakanathan HT; Rupali P; Zervos M; John Victor P; Veeraraghavan B
PLoS One; 2019; 14(12):e0227009. PubMed ID: 31887179
[TBL] [Abstract][Full Text] [Related]
11. Screening for Intermediately Vancomycin-Susceptible and Vancomycin-Heteroresistant Staphylococcus aureus by Use of Vancomycin-Supplemented Brain Heart Infusion Agar Biplates: Defining Growth Interpretation Criteria Based on Gold Standard Confirmation.
Khatib R; Riederer K; Sharma M; Shemes S; Iyer SP; Szpunar S
J Clin Microbiol; 2015 Nov; 53(11):3543-6. PubMed ID: 26311860
[TBL] [Abstract][Full Text] [Related]
12. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
[TBL] [Abstract][Full Text] [Related]
13. hVISA/VISA: diagnostic and therapeutic problems.
Szabó J
Expert Rev Anti Infect Ther; 2009 Feb; 7(1):1-3. PubMed ID: 19622051
[No Abstract] [Full Text] [Related]
14. Different Vancomycin-Intermediate Staphylococcus aureus Phenotypes Selected from the Same ST100-hVISA Parental Strain.
Di Gregorio S; Fernandez S; Cuirolo A; Verlaine O; Amoroso A; Mengin-Lecreulx D; Famiglietti A; Joris B; Mollerach M
Microb Drug Resist; 2017 Jan; 23(1):44-50. PubMed ID: 27991847
[TBL] [Abstract][Full Text] [Related]
15. Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia.
Howden BP; Smith DJ; Mansell A; Johnson PD; Ward PB; Stinear TP; Davies JK
BMC Microbiol; 2008 Feb; 8():39. PubMed ID: 18304359
[TBL] [Abstract][Full Text] [Related]
16. Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States.
Richter SS; Satola SW; Crispell EK; Heilmann KP; Dohrn CL; Riahi F; Costello AJ; Diekema DJ; Doern GV
J Clin Microbiol; 2011 Dec; 49(12):4203-7. PubMed ID: 21976769
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) emerged before the clinical introduction of vancomycin in Japan: a retrospective study.
Yamakawa J; Aminaka M; Okuzumi K; Kobayashi H; Katayama Y; Kondo S; Nakamura A; Oguri T; Hori S; Cui L; Ito T; Jin J; Kurosawa H; Kaneko K; Hiramatsu K
J Infect Chemother; 2012 Jun; 18(3):406-9. PubMed ID: 22033576
[TBL] [Abstract][Full Text] [Related]
18. Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.
Katayama Y; Murakami-Kuroda H; Cui L; Hiramatsu K
Antimicrob Agents Chemother; 2009 Aug; 53(8):3190-6. PubMed ID: 19451283
[TBL] [Abstract][Full Text] [Related]
19. "Slow VISA," a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3.
Saito M; Katayama Y; Hishinuma T; Iwamoto A; Aiba Y; Kuwahara-Arai K; Cui L; Matsuo M; Aritaka N; Hiramatsu K
Antimicrob Agents Chemother; 2014 Sep; 58(9):5024-35. PubMed ID: 24841271
[TBL] [Abstract][Full Text] [Related]
20. VraR Binding to the Promoter Region of
Dai Y; Chang W; Zhao C; Peng J; Xu L; Lu H; Zhou S; Ma X
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28289032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
